log in
Print | Back

Lowenstein Sandler LLP

Michael J. Lerner

Michael J. Lerner

Chair, Life Sciences Group


  • Corporate
  • Corporate Finance & Securities
  • Capital Markets & Securities
  • FDA Regulatory

WSG Practice Industries


Lowenstein Sandler LLP
New Jersey, U.S.A.


Michael provides strategic judgment and practical advice regarding diverse matters for pharmaceutical, life sciences, and health care companies. Clients–including public and private pharmaceutical, biotechnology, medical device, and other health care companies, as well as their investors and investment banks–value his extensive experience as both in-house counsel and outside legal and business advisor.

This background has contributed to Michael's stellar record of successful outcomes in product acquisitions and divestitures, technology licensing, sales and marketing practices, mergers and acquisitions, intellectual property, corporate compliance, employment law, and regulatory matters. Importantly, he understands the interplay of all these factors and how to manage them effectively for the optimum completion of each transaction.

Prior to joining Lowenstein Sandler, Michael was Senior Vice President and General Counsel of EKR Therapeutics, a specialty pharmaceutical company focusing on acute care hospital products. That position followed six years as Vice President and General Counsel at Reliant Pharmaceuticals Inc., which Michael helped grow into one of the nation's largest privately held pharmaceutical companies before it was acquired by GlaxoSmithKline in 2007. As part of Reliant's senior management team, he was lead inside lawyer on product acquisitions and dispositions totaling in excess of $650 million, and helped the company raise more than $660 million in equity and debt.

Earlier in his career, Michael was partner in charge of the pharmaceutical and life sciences practice at a midsize law firm, representing startup, specialty, and large pharmaceutical and other health care-related companies in corporate, partnering, and licensing matters.

Michael serves on the board of directors of the Blanche and Irwin Lerner Center for the Study of Pharmaceutical Management Issues at Rutgers Business School.

Bar Admissions

    New Jersey
    District of Columbia


Hofstra University School of Law (J.D. 1983)
Boston University (B.A. 1980), Business Administration, cum laude
Areas of Practice

Capital Markets & Securities | Corporate | Corporate Finance & Securities | FDA Regulatory | Life Sciences | Mergers & Acquisitions | The Tech Group | Transactions & Advisory Group | Venture Capital, Angel Investing, And M&A

Professional Career

Significant Accomplishments

Represented G Tech Bio, LLC in an exclusive out-licensing of a novel potential treatment or cure for Hepatitis B Virus (HBV) to Enochian Biosciences, Inc. Financial terms of the transaction were not disclosed.

Represented Matinas BioPharma Holdings, Inc. (NYSE:MTNB) in connection with a clinical stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions, in connection with an approximately $50 million public offering of common stock.

Represented CytoDyn, Inc., a clinical stage biopharmaceutical company, in its agreement to license the US rights to commercialize Leronlimab, a potential treatment for HIV, to Vyera Pharmaceuticals, LLS for up to $87.5 million in upfront and regulatory and sales-based milestone payments.

Represented Provention Bio, Inc., a clinical-stage biopharmaceutical company, in an underwritten offering common stock and concurrent private placement of common stock to Amgen Inc., totaling $66 million. SVB Leerink and Cantor Fitzgerald & Co. acted as joint book-running managers and H.C. Wainwright & Co. acted as lead manager for the public offering.

Represented Provention Bio, Inc. in the completion of asset purchase and a license agreement transactions involving clinical-stage assets with MacroGenics, totaling $700 million. The license agreement with MacroGenics provides Provention with exclusive global rights for the purpose of developing and commercializing MGDO10 (renamed PRV-3279), a humanized protein and a potential treatment for systemic lupus erythematosus (SLE) and other similar diseases. In the asset purchase agreement, Provention Bio acquired teplizumab (renamed PRV-031).

Represented Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) in a $15 Million  registered direct offering of its common stock. The proceeds from the offering will be used towards the continued advancement of the Company's clinical development programs of its investigational drug, Resunab. Corbus Pharmaceuticals, based in Massachusetts, is a clinical stage pharmaceutical company focusing on rare, life-threatening, chronic inflammatory diseases.

Represented Provention Bio (Nasdaq:PRVB), a clinical stage biopharmaceutical company, based in New Jersey, dedicated to intercepting and preventing immune-mediated diseases, in its $63.9 million initial public offering of shares of common stock.

Represented AzurRx BioPharma, Inc, a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, in the acquisition of expanded commercialization rights to MS1819-SD from Laboratories Mayoly Spindler, SAS.

Represented Enochian Biopharma Inc. in its sale to DanDrit Biotech USA, Inc. (OTCQB: DDRT), becoming a wholly owned subsidiary of DanDrit Biotech USA, Inc.

Represented Provention Bio, Inc. in the in-licensing of PRV300 from Janssen Pharmaceutica NV and Janssen Sciences Ireland UC.

Represented Provention Bio, Inc. in the in-licensing of PRV6527 from Janssen Pharmaceutica NV and Janssen Sciences Ireland UC.

Represented Provention Bio, Inc. in the in-licensing of an enterovirus vaccine platform to reduce the onset of type 1 diabetes from Vachtech Oy. Provention will use part of the $28.4 million founding financing invested by JDRF TID Fund to advance the program.

Represented Cranford Pharmaceuticals LLC in its sale of Inderal® XL to ANI Pharmaceuticals Inc. (Nasdaq: ANIP).

Represented Holmdel Pharmaceuticals in its sale of InnoPran® XL to ANI Pharmaceuticals Inc. (Nasdaq: ANIP).

Represented Metuchen Pharmaceuticals in their license agreement with VIVUS Inc. (NasdaqVVUS) for exclusive rights to commercialize STENDRA(R) (avanafil) in the U.S., Canada, South America, and India.

Represented Pernix Therapeutics in its acquisition of the Zohydro ER® Franchise from Zogenix.

Represented Celldex Therapeutics in connection with its $200.1 million public offering of common stock underwritten by Jefferies and Leerink Partners as joint book-running managers; Guggenheim Securities as lead manager; and Oppenheimer, Brean Capital, Cantor Fitzgerald, and ROTH Capital Partners as co-managers.

Represented Celldex Therapeutics in the negotiation of a clinical trial collaboration agreement with Roche to evaluate the safety, tolerability, and preliminary efficacy of Roche's investigational human monoclonal antibody MPDL3280A, a PD-L-1 immune checkpoint inhibitor, in combination with Celldex's targeting investigational antibody varlilumab.

Represented Celimmune LLC in connection with its licensing of a Phase 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen.

Represented Celldex Therapeutics in the negotiation of a clinical trial collaboration agreement with Bristol-Myers Squibb to evaluate the safety, tolerability, and preliminary efficacy of Opdivo, Bristol's l PD-1 immune checkpoint inhibitor, in combination with Celldex's targeting investigational antibody varlilumab.

Represented Matawan Pharmaceuticals in the acquisition of Tretinoin from Valeant Pharmaceuticals International.

Represented ContraVir Pharmaceuticals in connection with the license of CMX157 from Chimerix Inc.

Represented Alliqua Inc. in the acquisition of U.S. rights to Biovance and certain other extracellular matrix products from Celgene Inc.

Represented Pacira Pharmaceuticals Inc. in the license of bupivacaine liposome injectable suspension to Aratana Therapeutics for use in animal health.

Represented Cranford Pharmaceuticals LLC in the acquisition of Inderal LA from Pfizer.

Represented Regado Biosciences Inc. in a series of public and private offerings, including its $40 million initial public offering.

Speaking Engagements

Lowenstein Sandler was a Diamond sponsor of the 2016 28th Annual ROTH Conference. The event was a four-day conference that hosted 500 companies and 4,000 attendees, including institutional investors, private equity investors, VCs, company executives, and service providers working in the small and mid-cap space. In conjunction with the firm's sponsorship, we hosted the Keynote Presentation on Sunday, March 13, in which Michael Lerner introduced the keynote speaker, J. Craig Venter, Ph.D. We also hosted the Private Company Track on Tuesday, March 15, in which Jack Hogoboom and Steve Skolnick participated on a panel entitled "IPO Readiness." The panel reviewed the current market conditions, discussed the IPO market, and provided key insights for companies seeking public financing. To view the full video of the "IPO Readiness" panel, please click here.

Lawyers Steven Siesser, Jack Hogoboom, Michael Lerner, Steven Skolnick, Kate Basmagian, Sarah Saladini, Neeraj Kumar, and James O'Grady attended the conference.

Professional Activities and Experience

  • Life Science Star - LMG Life Sciences - (2011-2014)


    Changes on the Horizon for Clinical Research and Drug and Device Development: 21st Century Cures Act Becomes Law, December 14, 2016


Capital Markets Litigation
Lowenstein Sandler LLP 

Litigation News for the Global Financial Community

WSG's members are independent firms and are not affiliated in the joint practice of professional services. Each member exercises its own individual judgments on all client matters.

HOME | SITE MAP | GLANCE | PRIVACY POLICY | DISCLAIMER |  © World Services Group, 2020